Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharming Group ( (PHAR) ) has provided an update.
On September 10, 2025, Pharming Group N.V. announced its promotion from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective September 22, 2025. This advancement reflects the company’s strong growth momentum and is expected to enhance its visibility and attractiveness to investors, supporting its goal of becoming a leading global rare disease company.
The most recent analyst rating on (PHAR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall stock score is driven by strong technical analysis and positive earnings call sentiment, indicating potential growth. However, financial performance challenges, particularly in profitability and valuation, weigh down the score. The company’s stable balance sheet and cash flow improvements provide a foundation for future growth if profitability can be enhanced.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is engaged in the commercialization and development of innovative medicines, including small molecules and biologics, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific.
Average Trading Volume: 8,353
Technical Sentiment Signal: Buy
Current Market Cap: $994.9M
For an in-depth examination of PHAR stock, go to TipRanks’ Overview page.